Analysts' Actions: AAPL CAT DELL IBM HPQ


Apple AAPL rated new Neutral at Nomura. $710 price target. Growth could decelerate by 2014.

Allot Communications ALLT upgraded at Jefferies to Buy from Hold, Jefferies said. $30 price target. Verizon will soon begin ramping.

Aruba Networks ARUN upgraded to hold at TheStreet Ratings.

HomeAway AWAY upgraded to hold at TheStreet Ratings.

Cardinal Health CAH upgraded at ISI from Market Weight to Overweight, ISI Group said. $46 price target. Stock is already factoring in pricing fears with WAG and CVS.

Caterpillar CAT rated new Neutral at Piper. $90 price target. Mining segment is a long term strength, but an overhang in 2013.

Cymer CYMI rated new Outperform at CLSA. $60 price target. Leading stepper light source supplier.

Dell DELL rated new Sell at Citigroup. $8.50 price target. BYOD trends should pressure shares.

DirecTV DTV downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. $58 price target. Company will likely buy back fewer shares in the coming quarters.

Edison International EIX downgraded at Jefferies to Hold from Buy, Jefferies said. $51 price target. Valuation call.

Evercore Partners EVR rated new Neutral at UBS. $28 price target. Dilution risk could limit support the yield provides to the stock.

Greenhill GHL rated new Neutral at UBS. $52 price target. Premium valuations restored, further upside seems limited.

Hewlett-Packard HPQ rated new Sell at Citigroup. $13.50 price target. Needs clear strategic direction and leadership.

IBM IBM rated new Buy at Citigroup. $250 price target. One of the most compelling long term investments in tech.

Johnson & Johnson JNJ downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Valuation call, based on a $72 price target.

Lazard LAZ rated new Sell at UBS. $25 price target. Solid mature business, but valuation and expectations stretched.

Eli Lilly LLY upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $54 price target. Sola could reach the market in 3 to 4 years.

Netflix NFLX downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynch said. $72 price target. Valuation call, as the stock is up 31% over the past two weeks.

PACCAR PCAR rated new Overweight at Piper. $48.50 price target. Best positioned to benefit from a return to growth in the North American truck market.

Pier 1 Imports PIR rated new Buy at Deutsche. $25 price target. Company is leveraged to positive industry trends.

Progressive PRGS downgraded at Mizuho from Buy to Neutral, Mizuho said. $14.50 price target. Company is losing a key leader, which it will struggle to replace.

Pioneer Natural PXD rated new Outperform at Wells. Wolfcamp play should drive near-term growth.

Questcor Pharmaceuticals QCOR upgraded at Jefferies to Buy from Hold, Jefferies said. $28 price target. Limited downside with improved visibility.

Vertex Pharmaceuticals VRTX rated new Buy at Deutsche. $77 price target. New cystic fibrosis drug should be the next main driver.


Moody's MCO estimates, target increased at Piper.MCO estimates were raised through 2013, Piper Jaffray said. Company is leveraged to higher debt issuance rates. Overweight rating and new $55 price target.

Pentair PNR estimates, target raised at Credit Suisse. Shares of PNR now seen reaching $54, according to Credit Suisse. Estimates also increased, as the Tyco deal should add to earnings. Neutral rating.

Riverbed RVBD estimates, target boosted at ThinkEquity. Shares of RVBD now seen reaching $26, according to ThinkEquity. Estimates also upped, given higher expected demand and pricing. Buy rating.

>To submit a news tip, email:


Follow TheStreet on Twitter and become a fan on Facebook.

For less than $3 per week, you can get full access to Jim Cramer's intraday market commentary and stock trading strategies - sometimes before he says them on TV! Join now.

View Comments (0)